Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Pericarditis III: Medical Management

Pericarditis III: Medical Management

The primary objectives of managing pericarditis are to determine the underlying cause, provide effective therapy for treatment and symptom relief, and promptly detect signs and symptoms of cardiac tamponade. The following outlines the essential aspects of medical management for pericarditis:ObjectivesDetermine the Cause: Identifying the underlying cause of pericarditis is crucial for targeted treatment. Causes include viral infections, autoimmune diseases, post-cardiac injury syndrome, and...

Pericarditis IV: Nursing Management

Pericarditis IV: Nursing Management

Pericarditis, an inflammation of the pericardium, necessitates diligent nursing management to ensure effective patient care and recovery. The initial step in managing pericarditis is a comprehensive patient medical assessment.The patient reports chest pain aggravated by breathing, coughing, and swallowing, which worsens when lying supine. The pain often improves when sitting up and leaning forward. Additional symptoms may include fever, malaise, and, in severe cases, signs of heart failure.

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis II: Clinical Features and Diagnostic Tests

Pericarditis is distinguished by inflammation of the pericardium, the fibrous sac that encases the heart. It can be acute, lasting less than six weeks, or chronic, persisting for over three months. Understanding its clinical manifestations and diagnostic findings is crucial for timely and effective management.Clinical ManifestationsWhile pericarditis can be asymptomatic, it usually presents with characteristic symptoms such as:Chest Pain: The most characteristic symptom of pericarditis is chest...

Myocarditis III: Medical Management

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Pericarditis I: Introduction

Pericarditis I: Introduction

Pericarditis is defined as the inflammation of the pericardium, the thin, sac-like membrane surrounding the heart. This condition can cause significant chest pain and other symptoms, often necessitating medical intervention. The pericardium has two layers: the inner visceral layer and the outer parietal layer, separated by a small amount of fluid that reduces friction during heartbeats.Types of PericarditisPericarditis can be classified into several types based on the duration and nature of the...

Endocarditis III: Medical Management

Endocarditis III: Medical Management

Infective endocarditis management involves a multifaceted approach encompassing infection prevention, lifestyle modifications, pharmacological therapy, and surgical management.Infection Prevention:Hand Hygiene: Thorough handwashing is crucial to prevent the spread of infection. Hand hygiene should be performed regularly, especially before and after using the restroom.Oral Hygiene: Good oral hygiene is essential. It includes brushing teeth immediately after waking up and before bed, flossing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Colchicine in coronary heart disease: from inflammatory biology to secondary prevention.

Clinical and experimental rheumatology·2026

Same author

Incidental cardiac mass: when the past influences the future.

European heart journal. Imaging methods and practice·2026

Same author

One echocardiographic or hemodynamic parameter improves mortality prediction by the ESC/ERS four-strata model: a flexible approach to follow-up risk stratification in pulmonary arterial hypertension.

European heart journal. Quality of care & clinical outcomes·2026

Same author

Arrhythmic Myocarditis and Prevention of Sudden Cardiac Death: Current Evidence, Risk Stratification, and Management.

Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese·2026

Same author

[Ten clinical questions about recurrent or incessant pericarditis].

Giornale italiano di cardiologia (2006)·2026

Same author

Left atrial strain and fibrosis in primary mitral regurgitation: asynchronous markers of atrial remodelling?

International journal of cardiology·2026

Search research articles

Related Experiment Video

Updated: Jul 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

Management of pericarditis: recent advances.

Polish Archives of Internal Medicine

|June 30, 2026

Summary

Pericarditis management has evolved to a risk-stratified, imaging-supported approach. Interleukin-1 inhibition shows promise for recurrent pericarditis, reducing recurrences and corticosteroid use.

Area of Science:

Cardiology
Internal Medicine
Rheumatology

Background:

Pericarditis is a frequent cause of chest pain, with management shifting towards targeted therapies.
Diagnosis relies on clinical findings, supported by inflammatory biomarkers and advanced imaging like cardiac MRI.
Traditional treatment involves NSAIDs and colchicine, with corticosteroids reserved for specific cases.

Purpose of the Study:

To review the evolving management strategies for pericarditis.
To highlight the role of imaging and biomarkers in diagnosis and treatment decisions.
To discuss the emerging role of interleukin-1 inhibition in recurrent pericarditis.

Main Methods:

Clinical diagnosis based on chest pain, pericardial rub, ECG, and effusion.

More Related Videos

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava

Published on: February 27, 2017

Related Experiment Videos

Last Updated: Jul 1, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine

Published on: July 7, 2016

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava

Patch Angioplasty in the Rat Aorta or Inferior Vena Cava

Published on: February 27, 2017

Use of inflammatory biomarkers (e.g., C-reactive protein) and multimodality imaging (especially cardiac MRI).

First-line therapy with aspirin/NSAIDs plus colchicine; selective use of corticosteroids.

Evaluation of IL-1 inhibitors for refractory recurrent pericarditis.

Main Results:

A mechanism-based, risk-stratified, and imaging-supported approach is now standard.
IL-1 inhibition demonstrates efficacy in corticosteroid-dependent, colchicine-resistant recurrent pericarditis.
Biologics facilitate corticosteroid withdrawal and reduce recurrence rates.

Conclusions:

Recurrent pericarditis is increasingly recognized as an IL-1-mediated autoinflammatory condition.
IL-1 inhibitors represent a significant advance for specific patient subgroups.
Further research is needed on optimal treatment duration, cost-effectiveness, and personalized care.